LaFleur Minerals Inc. (CSE: LFLR,OTC:LFLRF) (OTCQB: LFLRF) (FSE: 3WK0) (‘LaFleur Minerals’ or the ‘Company’) is pleased to announce the launch of a brokered private placement of gold-linked convertible notes with a minimum principal amount of $4,000,000 and up to a maximum principal amount of $7,000,000 (the ‘Gold-Linked Note Financing’). Proceeds from the Gold-Linked Note Financing will be used for general corporate purposes as well as operations, equipment and other expenses related to the restart of the Company’s Beacon Gold Mill, a wholly-owned project with mine, mill and tailings pond located near Val d’Or, Québec, in Canada’s prolific Abitibi greenstone belt. Additional details on the Gold-Linked Note Financing are included below.

Gold Linked Note Financing:

• The Notes represent an unsecured obligation of the Company, and each Note may be converted, at the option of the holder, into common shares in the capital of the Company (‘Common Shares‘) at a price of $0.80 per Common Share.

• The Notes bear interest at a rate of 12% per annum on the aggregate principal amount of the Notes, calculated and payable semi-annually. The Notes will mature on or around November 30, 2028.

• The principal amount of Notes outstanding will be reduced by the Company on an annual basis on an annual basis (the ‘Principal Payment Dates‘), commencing on January 1, 2027, and ending with the final payment on November 30, 2028.

• FMI Securities Inc. (the ‘Agent‘) will be lead agent and sole bookrunner for the Gold-Linked Note Financing. In connection with the Gold-Linked Note Financing, and pursuant to the terms of an agency agreement to be entered into between the Company and the Agent, the Company will:
  • pay the Agent a cash fee equal to seven percent (7.0%) (reduced to four percent (4.0%) for any President’s List purchasers) of the gross proceeds from the sale of Notes, including any Notes sold pursuant to the Agents Option (defined herein); and
  • issue the Agent broker warrants (the ‘Broker Warrants‘) equal to seven percent (7.0%) (reduced to four percent (4.0%) for any President’s List purchasers) of the number of Notes sold in the Gold-Linked Note Financing. The Broker Warrants shall have an exercise price equal to $0.80 and will be exercisable for a period of two (2) years from the date of issuance.

• The Agent will have the option (the ‘Agents Option‘) to sell up to an additional $750,000 of the Notes, exercisable, in whole or in part, at any time up to 48 hours prior to the closing of the Gold-Linked Note Financing to cover over-allotments, if any.

All securities issued in connection with the Gold-Linked Note Financing will be subject to a statutory hold period of four months and one day following the date of issuance in accordance with applicable Canadian securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

QUALIFIED PERSON STATEMENT

All scientific and technical information contained in this news release has been prepared and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the Company and considered a Qualified Person (QP) for the purposes of NI 43-101.

About LaFleur Minerals Inc.
LaFleur Minerals Inc. (CSE: LFLR,OTC:LFLRF) (OTCQB: LFLRF) (FSE: 3WK0) is focused on the development of district-scale gold projects in the Abitibi Gold Belt near Val-d’Or, Québec. Our mission is to advance mining projects with a laser focus on our resource-stage Swanson Gold Project and the Beacon Gold Mill, which have significant potential to deliver long-term value. The Swanson Gold Project is approximately 18,304 hectares (183 km²) in size and includes several prospects rich in gold and critical metals previously held by Monarch Mining, Abcourt Mines, and Globex Mining. LaFleur has recently consolidated a large land package along a major structural break that hosts the Swanson, Bartec, and Jolin gold deposits and several other showings which make up the Swanson Gold Project. The Swanson Gold Project is easily accessible by road allowing direct access to several nearby gold mills, further enhancing its development potential. LaFleur Minerals’ fully-refurbished and permitted Beacon Gold Mill is capable of processing over 750 tonnes per day and is being considered for processing mineralized material at Swanson and for custom milling operations for other nearby gold projects.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding ‘Forward-Looking’ Information

This news release includes certain statements that may be deemed ‘forward-looking statements’. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words ‘expects’, ‘plans’, ‘anticipates’, ‘believes’, ‘intends’, ‘estimates’, ‘projects’, ‘potential’ and similar expressions, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’ or ‘should’ occur. Forward-looking statements in this news release include, without limitation, statements related to the Offering and anticipated use of proceeds therefrom. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Not for distribution to the United States newswire services or for dissemination in the United States

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273231

(TheNewswire)

GRANDE PRAIRIE, ALBERTA TheNewswire – Nov. 5, 2025 – Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) (‘ANGKOR’ OR ‘THE COMPANY’) announces the results of our North Bokor seismic program leading to the confirmation of a third anticlinal dome structure buried under the flat valley bottom lands within our Block VIII boundaries.

After identifying closed anticline structures in both South Bokor and Central Bokor on Block VIII, with potential drilling targets, finding another potentially closed anticline is very positive.  Angkor’s subsidiary EnerCam Resources Co. Cambodia Ltd. (‘EnerCam’) has now added a third potential target for oil and gas drilling in the coming year.  Finding and proving up a commercial hydrocarbon reservoir will define the first onshore hydrocarbon resource in the nation of Cambodia.

The North Bokor structure brings another anticline to our proposed targets on the west side of the Block VIII oil and gas license.  A noticeable difference from both the Central Bokor and South Bokor structures is that our mapped regional unconformity surface at North Bokor is found at significantly shallower depths.  The illustration below shows the crest is located between 150-200ms two-way-time (TWT) below surface, making this some 300-400 metres below the surface of the valley floor.

Click Image To View Full Size

Figure 1 – Interpolated structure of the North Bokor anticline from our 2D seismic program.

The North Bokor seismic does not confirm a closed structure, however management is confident that this anticline structure will prove to be closed based upon the surrounding physical features of the hills to the west and east of the North Bokor valley floor.  The illustration above clearly follows the general fold trend of the South and Central Bokor prospects, identified in recent disclosures.

(please see October 15, 2025 release: Angkor Resources IDENTIFIES SECOND DRILL TARGET FOR OIL & GAS ON ITS BLOCK VIII, CAMBODIA | Angkor Resources Corp. )

South Bokor and Central Bokor sub basins have identified significant closed anticline structures with approximately 48 and 60 square kilometres respectively of closure beneath the regionally mapped unconformity surface.

Click Image To View Full Size

Figure 1 : – Southwest to Northeast Seismic line showing the anticlinal expression developed in the Bokor North valley bottom and flanking hills.

Keith Edwards, Technical manager for EnerCam, comments on the seismic lines and what they tell readers:  ‘The fact that the regional unconformity surface we have been mapping is so close to the surface here means that we will have an easier time drilling down to some of our deeper targets in this part of our western half of Block VIII.’

Click Image To View Full Size

Figure 3: – A West to East Seismic line through the North Bokor Structure displaying general seismic stratigraphy across this sub basin.

ABOUT Angkor Resources CORPORATION:

Angkor Resources Corp. is a public company, listed on the TSX-Venture Exchange, and is a leading resource optimizer in Cambodia working towards mineral and energy solutions across Canada and Cambodia.

Its Cambodian energy subsidiary, EnerCam Resources, was granted an onshore oil and gas license of 7300 square kilometres in the southwest quadrant of Cambodia called Block VIII.   The company then removed all parks and protected areas and added 220 square kilometres, making the license just over 4095 square kilometres.  EnerCam is actively advancing oil and gas exploration activities onshore to meet its mission to prove Cambodia as an oil and gas producing nation.

Since 2022, Angkor’s Canadian subsidiary, EnerCam Exploration Ltd., has been involved in oil and gas production in Saskatchewan, Canada and undertaken carbon and gas capture to reduce emissions.  ANGKOR’s carbon capture and gas conservation project is part of its long-term commitment to Environmental and Social projects and cleaner energy solutions across jurisdictions.

The company’s mineral subsidiary, Angkor Gold Corp. in Cambodia holds two mineral exploration licenses in Cambodia with multiple prospects of copper and gold.

CONTACT: Delayne Weeks – CEO

Email:- info@angkorresources.com Website: angkor resources.com Telephone: +1 (780) 831-8722

Please follow @AngkorResources on , , , Instagram and .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

_____________________________________

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to the potential for gold and/or other minerals at any of the Company’s properties, the prospective nature of any claims comprising the Company’s property interests, the impact of general economic conditions, industry conditions, dependence upon regulatory approvals, uncertainty of sample results, timing and results o f future exploration, and the availability of financing.

Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

Copyright (c) 2025 TheNewswire – All rights reserved.

Falco Resources Ltd. (TSX-V:FPC) (‘ Falco ‘ or the ‘ Corporation ‘) is pleased to announce that it will begin a major exploration initiative across its significant holdings within the world-class Noranda Mining Camp (the ‘ Noranda Camp ‘), which is located in the region of Abitibi, Québec, starting with an Airborne Gravity Gradiometry (‘ AGG ‘) survey (the ‘ Survey ‘) over the next month. The Survey, a first for the region, will be utilized to identify new near surface Volcanogenic Massive Sulfide (‘ VMS ‘) type deposits. Falco is the largest claim holder in the Noranda Camp where over 19.0 Moz of gold equivalent was previously mined.

Luc Lessard, President and CEO of Falco, commented: ‘While the Horne 5 Project remains the Corporation’s primary focus, Falco is unique among peers as few, if any, gold exploration companies hold such a significant position in a world-class mining camp. With this modern exploration technology, we believe this survey offers an unprecedented opportunity to generate new discoveries in the Noranda Camp. The scale of the Noranda Camp and the prevalence of favorable geological formations to VMS mineralization was historically overwhelming for previous operators. Combining this new exploration approach with our extensive compilation of historical data, the potential to identify more VMS type deposits in the periphery of the Horne 5 Project Complex is very compelling.’

The Survey will be operated by Xcalibur MPH (Canada) Ltd. using their Falcon system known as FALCON fixed-wing AGG with a high-density grid of 100-meter line spacing providing exceptional resolution for detailed mapping. The Survey will be flown over 280 square kilometers across the majority of the Corporation’s land package, including the Noranda Camp, which includes 13 former mining sites for gold and base metals (see Figure below).

AGG surveys measure the change in density between the lighter host rock and denser sulfide mineralization. This sharp density contrast should be well identified by the Survey. Importantly, the majority of the rhyolitic units remain untested due to the scale of the property. Combined with the high-density contrast and expected shallow depths of mineralization, the Survey will provide an unprecedented opportunity to identify new VMS type targets at the Noranda Camp.

Results from the Survey are expected to be received for analysis in December 2025 and will complement the mining camp-scale digital compilation and geological reinterpretation of historical data. The integration of high-precision topographic data from the government-managed LIDAR survey will help define the structural controls associated with the distribution of high-grade mineralization. Consequently, the Corporation will define priority exploration targets in brownfield sites, with potential drilling to be determined based on the merit of the identified targets.

Stock Option Grant

The Corporation’s Board of Directors approved the grant of incentive stock options (the ‘ Options ‘) to key employees, officers, special advisors and directors to purchase up to an aggregate of 9,950,000 common shares of the Corporation (‘ Common Shares ‘). The Options are subject to a three-year vesting period and a five-year term. The Options are exercisable at an exercise price of $0.33 per Common Share being the closing price of the Common Shares on the TSX Venture Exchange on November 4, 2025.

Qualified Person

The scientific and technical information related to this press release has been reviewed and approved by Mr. Francois Goulet, independent consultant geologist. He is a Professional Geologist registered in Québec.

About Falco

Falco is one of the largest mineral claim holders in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 63,000 hectares of land in the Noranda Camp, which represents 63% of the camp as a whole and includes 13 former gold and base metal mining sites. Falco’s main asset is the Horne 5 project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Development Corp. is Falco’s largest shareholder, with an approximate 16% interest in the Corporation.

For further information, please contact:

Luc Lessard
President and Chief Executive Officer
514-261-3336
info@falcores.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release .

Cautionary Statement on Forward-Looking Information

This news release contains forward-looking statements and forward-looking information (together, ‘forward looking statements’) within the meaning of applicable securities laws. Often, but not always, forward-looking statements can be identified by words such as ‘plans’, ‘expects’, ‘seeks’, ‘may’, ‘should’, ‘could’, ‘will’, ‘budget’, ‘scheduled’, ‘estimates’, ‘forecasts’, ‘intends’, ‘anticipates’, ‘believes’, or variations including negative variations thereof of such words and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Specific forward-looking statements in this news release include, but are not limited to, statements with respect to; the expected timing, scope and results of the Survey; the ability of the Survey and related compilations to identify new VMS type targets at the Noranda Camp; the anticipated integration of high-precision topographic data from the government-managed LIDAR survey. These statements are made as of the date of this news release. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk factors set out in Falco’s annual and/or quarterly management discussion and analysis and in other of its public disclosure documents filed on SEDAR+ at www.sedarplus.ca, as well as all assumptions regarding the foregoing. Although the Corporation believes the forward-looking statements in this news release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. Consequently, the Corporation cautions investors that any forward-looking statements by the Corporation are not guarantees of future results or performance and that actual results may differ materially from those in forward-looking statements.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2c86a666-4d8b-479a-a4eb-96d3e18f6ff2

• The ESC M&PD meeting brings together the world’s experts working to improve the treatment of myocarditis and pericarditis.

• Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass.

• The Company will host a webcast conference call on December 1, 2025, to discuss the ARCHER findings and their significance, and to highlight the positive implications for Cardiol’s programs in inflammatory heart disease.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the full data from ARCHER, a randomized double-blind, placebo-controlled, multi-center Phase II clinical trial of CardiolRx in patients with acute myocarditis will be presented in an oral session at the Annual Meeting of the European Society of Cardiology (ESC) Working Group on Myocardial & Pericardial Disease (M&PD) in Trieste, Italy, on November 29, 2025.

Dr. Leslie T. Cooper, Jr., the Elizabeth C. Lane, Ph.D. and M. Nadine Zimmerman, Ph.D. Professor of Internal Medicine at the Mayo Clinic in Jacksonville, Florida, and Co-Chair of the Steering Committee for the ARCHER trial will present on behalf of the ARCHER investigators. Dr. Cooper’s presentation is expected to provide comprehensive insights into CardiolRx’s effects on myocardial inflammation and remodeling, highlighting a reduction in left ventricular mass comparable to that achieved with blockbuster therapies in obesity, hypertension, and heart failure, and implications for future development to address chronic inflammation in the broader heart failure population.

Dr. Andrew Hamer, Chief Medical Officer and Head of Research & Development of Cardiol Therapeutics, said: ‘The ESC M&PD meeting is an important global forum that unites leading clinicians and scientists advancing the understanding and treatment of myocarditis, pericarditis, and other inflammatory heart diseases. This year’s program is timely given the growing interest in and recognition of inflammation as a central driver of cardiac injury and remodeling. We are honored to have Dr. Cooper, one of the world’s foremost authorities in myocarditis, present the ARCHER results at this prestigious meeting dedicated to myopericardial diseases.’

‘The previously reported positive topline results from our Phase II ARCHER clinical trial provided compelling clinical proof of concept for CardiolRx, demonstrating notable improvements in cardiac structure after twelve weeks of blinded therapy in patients with acute myocarditis and preserved left ventricular function,’ said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. ‘These findings represent the first evidence of a drug’s efficacy on structural recovery and reverse remodeling in this patient population, underscoring the potential of CardiolRx to address the underlying inflammatory processes driving myocardial injury. The forthcoming presentation will further characterize the therapeutic profile of CardiolRx as a novel, anti-inflammatory strategy with the potential to significantly improve the treatment landscape not only for acute myocarditis, but also for the broader population of patients suffering from chronic heart failure, where inflammation is a fundamental mechanism leading to the development and progression of disease.’

ARCHER enrolled 109 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel, and investigated the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis. The design and rationale for ARCHER were published on June 27, 2024, in the journal ESC Heart Failure (pubmed.ncbi.nlm.nih.gov/38937900/).

Company Webcast Conference Call Information

Cardiol will host a webcast conference call at 8:30 a.m. EST on December 1, 2025, following the presentation at the ESC M&PD meeting. Members of the Company’s management team will discuss the clinical findings of the ARCHER trial, implications for future development, and next steps in advancing Cardiol’s programs in inflammatory heart disease. To participate by telephone, please dial 877-346-6112 (Canada and the United States) or +1-848-280-6350 (International). The conference call with also be broadcast live online through a listen-only webcast (with slides), which will be posted under ‘Events & Presentations’ in the Investors section of the Cardiol website and archived for approximately 90 days.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

The ARCHER Program (NCT05180240) comprises the completed Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for use in heart failure, the Company’s intention to present and publish comprehensive ARCHER trial data, the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis, the expected content of Dr. Cooper’s presentation, and the date, timing and purpose of the Company’s December 1, 2025 webcast. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273250

(TheNewswire)

Toronto, Ontario November 5, 2025 TheNewswire – Noble Mineral Exploration Inc. ( ‘Noble’ or the ‘Company’ ) (TSX-V:NOB, FRANKFURT: NB7, OTCQB:NLPXF) is pleased to report acquisition of mining claims on a Rare Earth prospect in Northern Quebec.  The 90 claims were acquired by map staking to cover approximately 4,465 hectares and is called the Mehmet Property

The Mehmet Earth Property

The Mehmet Property is located about 163 kilometers east of Schefferville on the Quebec-Labrador Border.  It forms a circular shaped, magnetic structure about 10 kilometers across and is classed by the Quebec Government as an hyperalkaline rock with associated rare metals. The mineralization is in an alkali feldspar and clinopyroxene syenite containing an abnormally high amount of allanite crystals as well as numerous allanite-filled microfractures.  The rock type was described as a fractured, alkali feldspar, syenite with clinopyroxene, allanite, apatite, fluorite and magnetite.

Rock analyses by the Quebec Government include (Sigeom Sample 1986016233) :

• 2157.1 ppm total rare earth elements (of which 114.4 ppm are heavy ETR).

• 2144.6 ppm Zirconium,

• 392.7 ppm Neodymium,

• 135.3 ppm Yttrium,

• 26.1 ppm Thorium, and

• 71.5 ppm Niobium

Besides the Quebec government sampling, very little exploration work has been done on the property.

Click Image To View Full Size

Figure 1: Regional setting of the Mehmet Property on a regional magnetic background.

The Mehmet Property is located about 65 km southwest of the Crater Lake Property where Scandium Canada has defined a rare earth and scandium resource. (See Figure 1)

Click Image To View Full Size

Chart 1: Defined Resource at the Crater Lake Project owned by Scandium Canada.  Source: NI 43-101 Technical Report and Updated Mineral Resource Estimate for the Crater Lake Project, Quebec, Canada: Marina Lund, P.Geo., M.Sc., Simon Boudreau, P.Eng., Marc R. Beauvais, P.Eng: 2025

Acquisition of the Mehmet Property demonstrates Noble’s commitment to exploring for critical minerals in Canada.

Wayne Holmstead, P.Geo (OGQ#10434), a ‘qualified person’ as such term is defined by National Instrument 43-101, has reviewed the data disclosed in this news release, and has otherwise reviewed and approved the technical information in this news release on behalf of Noble Minerals.

About Noble Mineral Exploration Inc.

Noble Mineral Exploration Inc. is a Canadian-based junior exploration company, which has holdings of securities in Canada Nickel Company Inc., Homeland Nickel Inc., East Timmins Nickel Inc. (20%), and its interest in the Holdsworth gold exploration property in the area of Wawa, Ontario.

Noble holds mineral and/or exploration rights in ~70,000ha in Northern Ontario and ~14,000ha elsewhere in Quebec upon which it plans to generate option/joint venture exploration programs.

Noble holds mineral rights and/or exploration rights in ~18,000 hectares in the Timmins-Cochrane areas of Northern Ontario known as Project 81, ~2,215 hectares in Thomas Twp/Timmins, as well as an additional 20% interest in ~38,700 hectares in the Timmins area and ~175 hectares of mining claims in Central Newfoundland. Project 81 hosts diversified drill-ready gold, nickel-cobalt and base metal exploration targets at various stages of exploration. Noble also holds ~4,600 hectares in the Nagagami Carbonatite Complex and its ~3,200 hectares in the Boulder Project both near Hearst, Ontario.  ~3,700 hectares in the Buckingham Graphite Property, ~10,152 hectares in the Havre St Pierre  Nickel, Copper, PGM property, and ~1,573 hectares in the Cere-Villebon Nickel, Copper, PGM property, ~569 hectare Uranium/Rare Earth property (Chateau) and a ~461 hectare Uranium/Molybdenum property (Taser North), 4,465 hectares REE Mehmet Property all of which are in the province of Quebec.

Noble’s common shares trade on the TSX Venture Exchange under the symbol ‘NOB.’

More detailed information on Noble is available on the website at www.noblemineralexploration.com .

Noble’s common shares trade on the TSX Venture Exchange under the symbol ‘NOB’.

Cautionary Statement

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

The foregoing information may contain forward-looking statements relating to the future performance of Noble Mineral Exploration Inc. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially from the Company’s plans and expectations. These plans, expectations, risks and uncertainties are detailed herein and from time to time in the filings made by the Company with the TSX Venture Exchange and securities regulators.  Noble Mineral Exploration Inc. does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

H. Vance White, President

Phone:        416-214-2250

Fax:                416-367-1954

Email: info@noblemineralexploration.com

Investor Relations: ir@noblemineralexploration.com

Copyright (c) 2025 TheNewswire – All rights reserved.